



Canaccord Growth Conference Investor Presentation

John McCutcheon
President and CEO
August 2025

Pillars of Success

*Developer of the world's first and only leadless pacemaker for heart failure
Listed on ASX (symbol EBR) since 2021 and SEC registrant since 2024*

Significant Growth Potential



Unique solution

WiSE System is complementary to other cardiac pacing devices and is the only leadless device that can pace the left ventricle for heart failure



Large market opportunity

Targeting an initial addressable market of US\$3.6bn in the US




FDA approved

US FDA approval received 11 April 2025 supported by Breakthrough Device Designation and compelling clinical data



Strong reimbursement

Inpatients: CMS approved NTAP add-on payments commencing Oct 2025
Outpatients: CMS has granted preliminary approval for TPT payment expected to commence Oct 2025



Clear commercial strategy

Pilot launch underway. Limited Market Release (LMR) to commence Q4 2025 to coincide with reimbursement add-on payments




Manufacturing facilities in place

New facility under construction to support commercial growth and scale
Expect full transition to new facility by the end of H1 2026


Cardiac Rhythm Management Market

Comprised of three key segments

Worldwide CRM Market (~US\$13.6bn)¹



- Cardiac Resynchronisation Therapy (CRT)
- Implantable Cardioverter Defibrillation (ICD)
- Pacemakers



Leads – The Achilles' Heel of Cardiac Rhythm Management

Traditional CRT systems use wires or leads to deliver energy to the heart, which can lead to many problems.




Leads can migrate and fracture



Leads can become infected - a pathway for pathogens to reach the myocardium



Cannot be placed inside (endocardially) the left ventricle



Left Ventricle (LV) lead must be placed outside the heart to avoid blood clots



Higher risk of complications with a lead-based upgrade to CRT



Risks increase as the number of leads increases

Market is Rapidly Adopting Leadless Devices as Standard

EBR's WiSE System is the only leadless device that can deliver leadless left ventricle pacing for cardiac resynchronization therapy

WiSE System fills the gap

The only leadless solution for left ventricle (LV) endocardial pacing

Other wireless pacemakers are too big for LV pacing

Their size increases the risk of blood clots, restricting their use to right ventricle (RV) and right atrium (RA) pacing only

Complementary solution

WiSE System can be used in conjunction with leadless pacemakers to deliver totally leadless CRT

Strong competitive protection

WiSE System is protected by over 97 issued patents globally

Left ventricle¹



EBR Systems
WiSE Electrode



Right ventricle / atrium¹



Medtronic
Micra®



Boston
Scientific
Empower®



Abbott
Aveir®

Extravascular / Subcutaneous ICD¹




Boston
Scientific
Emblem®



Medtronic
Aurora®


WiSE System for Heart Failure Patients

Designed to overcome the limitations of conventional lead-based CRT



Leadless

Ultra-compact device removes constraints of lead-based pacing systems



Versatile

Open platform synchronizes with a range of existing pacing devices




LV Endocardial Pacing (LVEP)

Directly stimulates the heart's natural conduction system

Targeting a \$3.6bn Total Addressable Market

Total addressable market represents patients with limited or no other options



Upgrade of a leadless pacemaker with WiSE to provide totally leadless CRT

Total Addressable market (~\$3.6bn)²

Leadless Upgrades (~17K patients/yr)

- Patients with a leadless right ventricle pacemaker can only upgrade with WiSE CRT System to receive effective CRT
- WiSE CRT System paired with leadless pacemakers*

Rapidly growing segment

High Risk Upgrades (~20K patients/yr)


Patient requiring CRT, but is deemed too high risk for a conventional CS lead placement

Acute Lead Failure (~11K patients/yr)

Unable to implant CRT wire in a new CRT patient.

Chronic Lead Failure (~32K patients/yr)

Traditional CRT system implanted but has ceased to provide effective CRT



*Medtronic's Micra leadless pacemaker has been qualified for use with WiSE CRT.
Abbott's Aveir leadless pacemaker has not yet been qualified for use with WiSE CRT, but testing conducted by EBR is in progress.

Executing a Clear Commercialization Strategy



Reimbursement provides significant tailwinds

- ✓ Inpatient New Technology Add-on Payments (NTAP¹) approved by CMS commencing October 1, 2025
- ✓ Outpatient Transitional Pass-Through (TPT¹) payments pending final ruling, expected to commence October 1, 2025
- ✓ First technology accepted into the Transitional Coverage for Emerging Technologies (TCET) program for transitional national coverage decision;



Disciplined approach to commercialization, limiting execution risk

- ✓ First sales achieved in 2Q '25 during pilot phase
- ✓ Limited Market Release (LMR) beginning 4Q '25 coinciding with initiation of add-on and pass-through payments
- ✓ Focused subset of strategic hospitals to be targeted
- ✓ Significant support and advocacy from US physicians



Continued investment in expanding commercial leadership team and sales force

- ✓ Investment into leadership team including appointment of Chief Commercial Officer and 2 VPs of Sales and a VP of Marketing
- ✓ Direct sales force with 8 territories in place by year end 2025, each consisting of a sales rep and a clinical / technical specialist

WiSE Reimbursement

As a new medical device, EBR's WiSE System has unprecedented access to reimbursement

Medicare In-patient Payment

New Technology Add-On Payment (NTAP)

- CMS has approved the NTAP payment for WiSE
- NTAP payments to commence October 2025
- Add-on payments based on \$63,300 ASP

Benefits of NTAP:

- Designed to cover the increased cost of important new technologies
- Reduced financial barriers for sites and improves access
- Validates the technology's innovation and clinical benefit

Medicare Out-patient Payment

Transitional Pass-Through (TPT) Payment

- CMS has recommended approval for WiSE up to \$63,300 ASP
- Expected to commence October 2025

Benefits of TPT:

- Covers cost of WiSE system
- Reduced financial barriers for sites and improves access
- External validation that the technology represents a meaningful clinical advancement

Medicare Coverage

Transitional Coverage of Emerging Technologies (TCET)

- WiSE is **first** technology to be accepted into the TCET program
- Developing Coverage with Evidence (CED) protocol

Benefits of TCET:

- Early CMS engagement for an efficient review process
- Transitional NCD for up to 5 years
- Expedited Medicare coverage

World Class Manufacturing Facility

EBR has secured a new state-of-the-art facility to support long-term commercial growth and scale

Significant Facility Expansion:

- New 11-year lease secured for 51,000 sq ft (4,751 sqm) facility
- Expansion of capability from critical manufacturing processes to manufacture of complete units
- Expands EBR's manufacturing capacity to accommodate future growth and demand for WiSE

Phased Financial Commitment:

- Rent payments deferred until January 2026
- Gradual space occupancy and rent scaling up annually to full occupancy by year four
- Landlord to finance approximately US\$4m in tenant improvements

Timing:


- Facility upgrades and qualifications to be completed progressively over the next year, with full transition to the new facility expected in H1 2026



State-of-the-art facility in Santa Clara, California

Major Milestones

Proven track record of achieving major clinical, regulatory, and reimbursement milestones



Leadership Team



John McCutcheon
**PRESIDENT & CHIEF
EXECUTIVE OFFICER**

- CEO since 2019
- 40+ years of sales, marketing and leadership experience in med device
- Lengthy CEO and M&A background



Gary Doherty
CHIEF FINANCIAL OFFICER

- CFO since 2023
- 35+ years of finance and accounting experience
- Led 2020 Nasdaq IPO for Acutus Medical



Erik Strandberg
**CHIEF COMMERCIAL
OFFICER**

- CCO since 2024
- Over two decades of med device sales experience and related leadership
- Strategic planning and product portfolio management



Michael Hendricksen
CHIEF OPERATING OFFICER

- COO since 2021
- Extensive product development and manufacturing experience, scaling and integrating operations



Pharoah Garma
**CHIEF REGULATORY
OFFICER**

- CRO since 2024
- Sr. FDA Reviewer prior to leadership roles at various startups and multinationals.
- COO at Boomerang Medical



Spencer H. Kubo, M.D.
MEDICAL MONITOR

- CMO 2019-2025
- Lengthy experience as CMO, in clinical trial oversight, and in various academic roles



Andrew Shute
**CHIEF CORPORATE
DEVELOPMENT OFFICER**

- SVP Global Field Ops / CCDO since 2015
- Strong clinical training and sales experience
- Integral role in investor relations



N. Parker Willis
**CHIEF TECHNOLOGY
OFFICER**

- CTO since 2011
- Extensive signal processing experience in medical devices and development for novel cardiac EP



Board of Directors:

Allan Will

EXECUTIVE CHAIRMAN

Bronwyn Evans, Ph.D.

DIRECTOR

Christopher Nave, Ph.D.

DIRECTOR

Karen Drexler

DIRECTOR

Trevor Moody

DIRECTOR

David Steinhaus, M.D.

DIRECTOR

John McCutcheon

DIRECTOR, PRESIDENT & CEO

Summary

EBR is poised for success to deliver superior treatment for patients suffering from cardiac rhythm diseases



Developer of the world's first and only leadless pacing system for heart failure



EBR's WiSE® System has no direct competitors and is complementary to other pacemaker technologies



FDA approved and reimbursement in place supporting attractive ASP



Significant market opportunity with an initial addressable market of \$3.6bn



Disciplined commercialization strategy in place focusing on high-volume sites in the US, minimizing execution risk



Thank You

www.ebrsystemsinc.com